This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
Investigators will carry out validation of a laboratory assay to detect SARS-CoV-2 nucleic acids in human saliva samples. Data for the validation will include the test results from standard nasopharyngeal (NP) swabs (controls) AND matched saliva samples (experimental group) of individuals who are either known to be infected or at high risk of being infected. Investigators hypothesize that the performance of an assay designed specifically for saliva will not perform differently, as defined by a predetermined margin, from the standard assay performed on NP and other respiratory samples
Study Type
OBSERVATIONAL
Enrollment
67
The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
Ambry Genetics
Aliso Viejo, California, United States
Detection of COVID-19 SARs-CoV-2 in saliva samples versus nasopharyngeal samples
TaqPath RT-PCR assay performed on saliva compared to TaqPath RT-PCR performed on nasopharyngeal samples for assay accuracy, concordance, reproducibility/precision, analytical sensitivity and analytical specificity.
Time frame: up to 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.